Esperion beat Sarepta yesterday, closing above $80 while SRPT was about a point behind.
Today is a different story. ESPR is slightly down, but SRPT is up another 4 percent. Investors are getting excited about the imminent FDA approval of Sarepta's muscular dystrophy drug.
I'll be looking for an exit point in the coming days. The stock has risen on news, but the reality is that the market for SRPT's drug isn't big. In the long run, ESPR is a far better bet.


Gold is $1,581/oz today. When it hits $2,000, it will be up 26.5%. Let's see how long that takes. - De 3/11/2013 - ANSWER: 7 Years, 5 Months